Brief: Aim Immunotech Completes Treatment Of Last Subject In Phase 2 Study Evaluating Ampligen® For The Treatment Of Post-Covid Conditions
21/11/2023 18:48
Nov 21 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH COMPLETES TREATMENT OF LAST SUBJECT IN
PHASE 2
STUDY EVALUATING AMPLIGEN® FOR THE TREATMENT OF POST-COVID
CONDITIONS
* AIM IMMUNOTECH INC- TOPLINE DATA EXPECTED AS EARLY AS Q1
2024
* AIM IMMUNOTECH INC- NO SEVERE ADVERSE EVENTS REPORTED TO
DATE
Source text for Eikon: ID:nGNX9sdvJG
Further company coverage: AIM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential